Document Detail


Influence of boost technique (external beam radiotherapy or brachytherapy) on the outcome of patients with carcinoma of the base of the tongue.
MedLine Citation:
PMID:  7718261     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We reviewed 90 patients with squamous cell carcinoma of the base of the tongue. Fifty-three patients were treated with external beam radiotherapy alone (3 T1, 11 T2, 21 T3, and 18 T4 tumors) and thirty-seven patients were treated with external beam radiotherapy plus brachytherapy boost (4 T1, 15 T2, 11 T3, and 7 T4 tumors). For patients with T1, T2 and T3 primaries, the actuarial 3-year local relapse-free survival was 42% following external beam radiotherapy alone and 67% following external beam radiotherapy plus brachytherapy (p < 0.05). The actuarial 3-year cause specific survival for these T-stages was 37% for patients treated with external beam radiotherapy alone and 53% for patients treated with external beam radiotherapy plus brachytherapy (p = 0.1). In the Cox multivariate analyses restricted patients with T1, T2 and T3 staged tumors, treatment modality was the only predictor for local control but no influence on specific survival was found. The trend towards significant differences in specific survival found in the univariate comparison of both treatment modalities was probably due to the significantly higher number of N-positive patients treated with external beam radiotherapy alone. When all stages were included in the Cox analysis, low hemoglobin level, invasion of deep muscle, number of palpable nodes, and history of weight loss significantly influenced the outcome. Soft tissue necrosis occurred more frequently in patients treated with external beam radiotherapy plus brachytherapy (33% vs. 10%, p = 0.52).
Authors:
C A Regueiro; I Millán; A de la Torre; F J Valcárcel; R Magallón; E Fernández; G Aragón
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Acta oncologica (Stockholm, Sweden)     Volume:  34     ISSN:  0284-186X     ISO Abbreviation:  Acta Oncol     Publication Date:  1995  
Date Detail:
Created Date:  1995-05-25     Completed Date:  1995-05-25     Revised Date:  2009-05-12    
Medline Journal Info:
Nlm Unique ID:  8709065     Medline TA:  Acta Oncol     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  225-33     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, Clínica Puerta de Hierro, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use
Brachytherapy / adverse effects
Carcinoma, Squamous Cell / drug therapy,  mortality,  radiotherapy*
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Radiotherapy / adverse effects
Retrospective Studies
Risk Factors
Survival Rate
Tongue / pathology,  radiation effects
Tongue Neoplasms / drug therapy,  mortality,  radiotherapy*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and...
Next Document:  Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resi...